Skip to main content
Erschienen in: Diabetologia 6/2015

01.06.2015 | Article

Lack of the protein tyrosine phosphatase PTPN22 strengthens transplant tolerance to pancreatic islets in mice

verfasst von: Georgia Fousteri, Tatiana Jofra, Roberta Di Fonte, Nicola Gagliani, Cristina Morsiani, Angela Stabilini, Manuela Battaglia

Erschienen in: Diabetologia | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Protein tyrosine phosphatase non-receptor 22 (PTPN22) plays a central role in T cell, B cell and innate immune cell signalling. A genetic variation in Ptpn22 is considered a major risk factor for the development of type 1 diabetes and has been the subject of extensive study. While several reports have addressed how Ptpn22 might predispose to autoimmunity, its involvement in other immune-mediated diseases, such as allograft rejection, has not been explored.

Methods

To address a possible function for Ptpn22 in allograft rejection, we used a mouse model of pancreatic islet transplantation. We performed transplant tolerance experiments and determined how PTPN22 shapes tolerance induction and maintenance.

Results

Ptpn22 −/− recipient mice generate higher numbers of alloreactive T cells after allogeneic pancreatic islet transplantation compared with wild-type (WT) mice, but reject grafts with similar kinetics. This is not only due to their well-documented increase in forkhead box protein P3 (FOXP3)+ T regulatory (Treg) cells but also to the expansion of T regulatory type 1 (Tr1) cells caused by the lack of PTPN22. In addition, a tolerogenic treatment known to induce transplant tolerance in WT mice via Tr1 cell generation is more effective in Ptpn22 −/− mice as a consequence of boosting both Tr1 and FOXP3+ Treg cells.

Conclusions/interpretation

A lack of PTPN22 strengthens transplant tolerance to pancreatic islets by expanding both FOXP3+ Treg and Tr1 cells. These data suggest that targeting PTPN22 could serve to boost transplant tolerance.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bottini N, Peterson EJ (2013) Tyrosine phosphatase PTPN22: multifunctional regulator of immune signaling, development, and disease. Annu Rev Immunol 32:83–119CrossRefPubMed Bottini N, Peterson EJ (2013) Tyrosine phosphatase PTPN22: multifunctional regulator of immune signaling, development, and disease. Annu Rev Immunol 32:83–119CrossRefPubMed
2.
Zurück zum Zitat Stanford SM, Bottini N (2014) PTPN22: the archetypal non-HLA autoimmunity gene. Nat Rev Rheumatol 10:602–611CrossRefPubMed Stanford SM, Bottini N (2014) PTPN22: the archetypal non-HLA autoimmunity gene. Nat Rev Rheumatol 10:602–611CrossRefPubMed
3.
Zurück zum Zitat Fousteri G, Liossis SN, Battaglia M (2013) Roles of the protein tyrosine phosphatase PTPN22 in immunity and autoimmunity. Clin Immunol 149:556–565CrossRefPubMed Fousteri G, Liossis SN, Battaglia M (2013) Roles of the protein tyrosine phosphatase PTPN22 in immunity and autoimmunity. Clin Immunol 149:556–565CrossRefPubMed
4.
Zurück zum Zitat Stanford S, Mustelin T, Bottini N (2010) Lymphoid tyrosine phosphatase and autoimmunity: human genetics rediscovers tyrosine phosphatases. Semin Immunopathol 32:127–136CrossRefPubMedCentralPubMed Stanford S, Mustelin T, Bottini N (2010) Lymphoid tyrosine phosphatase and autoimmunity: human genetics rediscovers tyrosine phosphatases. Semin Immunopathol 32:127–136CrossRefPubMedCentralPubMed
5.
Zurück zum Zitat Gjorloff-Wingren A, Saxena M, Williams S, Hammi D, Mustelin T (1999) Characterization of TCR-induced receptor-proximal signaling events negatively regulated by the protein tyrosine phosphatase PEP. Eur J Immunol 29:3845–3854CrossRefPubMed Gjorloff-Wingren A, Saxena M, Williams S, Hammi D, Mustelin T (1999) Characterization of TCR-induced receptor-proximal signaling events negatively regulated by the protein tyrosine phosphatase PEP. Eur J Immunol 29:3845–3854CrossRefPubMed
6.
Zurück zum Zitat Wu DJ, Zhou W, Enouz S et al (2014) Autoimmunity-associated LYP-W620 does not impair thymic negative selection of autoreactive T cells. PLoS One 9:e86677CrossRefPubMedCentralPubMed Wu DJ, Zhou W, Enouz S et al (2014) Autoimmunity-associated LYP-W620 does not impair thymic negative selection of autoreactive T cells. PLoS One 9:e86677CrossRefPubMedCentralPubMed
7.
Zurück zum Zitat Hasegawa K (2004) PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells. Science 303:685–689CrossRefPubMed Hasegawa K (2004) PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells. Science 303:685–689CrossRefPubMed
8.
Zurück zum Zitat Salmond RJ, Brownlie RJ, Morrison VL, Zamoyska R (2014) The tyrosine phosphatase PTPN22 discriminates weak self peptides from strong agonist TCR signals. Nat Immunol 15:875–883CrossRefPubMedCentralPubMed Salmond RJ, Brownlie RJ, Morrison VL, Zamoyska R (2014) The tyrosine phosphatase PTPN22 discriminates weak self peptides from strong agonist TCR signals. Nat Immunol 15:875–883CrossRefPubMedCentralPubMed
9.
Zurück zum Zitat Arechiga AF, Habib T, He Y et al (2009) Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J Immunol 182:3343–3347CrossRefPubMedCentralPubMed Arechiga AF, Habib T, He Y et al (2009) Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J Immunol 182:3343–3347CrossRefPubMedCentralPubMed
10.
Zurück zum Zitat Rieck M, Arechiga A, Onengut-Gumuscu S, Greenbaum C, Concannon P, Buckner J (2007) Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol 179:4704–4710CrossRefPubMed Rieck M, Arechiga A, Onengut-Gumuscu S, Greenbaum C, Concannon P, Buckner J (2007) Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol 179:4704–4710CrossRefPubMed
11.
Zurück zum Zitat Habib T, Funk A, Rieck M et al (2012) Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant. J Immunol 188:487–496CrossRefPubMedCentralPubMed Habib T, Funk A, Rieck M et al (2012) Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant. J Immunol 188:487–496CrossRefPubMedCentralPubMed
12.
Zurück zum Zitat Wang Y, Shaked I, Stanford SM et al (2013) The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity. Immunity 39:111–122CrossRefPubMed Wang Y, Shaked I, Stanford SM et al (2013) The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity. Immunity 39:111–122CrossRefPubMed
13.
Zurück zum Zitat Bottini N, Musumeci L, Alonso A et al (2004) A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 36:337–338CrossRefPubMed Bottini N, Musumeci L, Alonso A et al (2004) A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 36:337–338CrossRefPubMed
14.
Zurück zum Zitat Bottini N, Vang T, Cucca F, Mustelin T (2006) Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin Immunol 18:207–213CrossRefPubMed Bottini N, Vang T, Cucca F, Mustelin T (2006) Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin Immunol 18:207–213CrossRefPubMed
15.
Zurück zum Zitat Criswell LA, Pfeiffer KA, Lum RF et al (2005) Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am J Hum Genet 76:561–571CrossRefPubMedCentralPubMed Criswell LA, Pfeiffer KA, Lum RF et al (2005) Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am J Hum Genet 76:561–571CrossRefPubMedCentralPubMed
16.
Zurück zum Zitat Zhang J, Zahir N, Jiang Q et al (2011) The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat Genet 43:902–907CrossRefPubMed Zhang J, Zahir N, Jiang Q et al (2011) The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat Genet 43:902–907CrossRefPubMed
17.
Zurück zum Zitat Aarnisalo J, Treszl A, Svec P et al (2008) Reduced CD4+T cell activation in children with type 1 diabetes carrying the PTPN22/Lyp 620Trp variant. J Autoimmun 31:13–21CrossRefPubMed Aarnisalo J, Treszl A, Svec P et al (2008) Reduced CD4+T cell activation in children with type 1 diabetes carrying the PTPN22/Lyp 620Trp variant. J Autoimmun 31:13–21CrossRefPubMed
18.
Zurück zum Zitat Vang T, Congia M, Macis M et al (2005) Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 37:1317–1319CrossRefPubMed Vang T, Congia M, Macis M et al (2005) Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 37:1317–1319CrossRefPubMed
19.
Zurück zum Zitat Brownlie RJ, Miosge LA, Vassilakos D, Svensson LM, Cope A, Zamoyska R (2012) Lack of the phosphatase PTPN22 increases adhesion of murine regulatory T cells to improve their immunosuppressive function. Sci Signal 5:ra87CrossRefPubMed Brownlie RJ, Miosge LA, Vassilakos D, Svensson LM, Cope A, Zamoyska R (2012) Lack of the phosphatase PTPN22 increases adhesion of murine regulatory T cells to improve their immunosuppressive function. Sci Signal 5:ra87CrossRefPubMed
20.
Zurück zum Zitat Zikherman J, Hermiston M, Steiner D, Hasegawa K, Chan A, Weiss A (2009) PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background. J Immunol 182:4093–4106CrossRefPubMedCentralPubMed Zikherman J, Hermiston M, Steiner D, Hasegawa K, Chan A, Weiss A (2009) PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background. J Immunol 182:4093–4106CrossRefPubMedCentralPubMed
21.
22.
Zurück zum Zitat Chang HH, Miaw SC, Tseng W et al (2013) PTPN22 modulates macrophage polarization and susceptibility to dextran sulfate sodium-induced colitis. J Immunol 191:2134–2143CrossRefPubMed Chang HH, Miaw SC, Tseng W et al (2013) PTPN22 modulates macrophage polarization and susceptibility to dextran sulfate sodium-induced colitis. J Immunol 191:2134–2143CrossRefPubMed
23.
Zurück zum Zitat Maine CJ, Marquardt K, Cheung J, Sherman LA (2014) PTPN22 controls the germinal center by influencing the numbers and activity of t follicular helper cells. J Immunol 192:1415–1424CrossRefPubMedCentralPubMed Maine CJ, Marquardt K, Cheung J, Sherman LA (2014) PTPN22 controls the germinal center by influencing the numbers and activity of t follicular helper cells. J Immunol 192:1415–1424CrossRefPubMedCentralPubMed
24.
Zurück zum Zitat Zheng P, Kissler S (2013) PTPN22 silencing in the NOD model indicates the type 1 diabetes-associated allele is not a loss-of-function variant. Diabetes 62:896–904CrossRefPubMedCentralPubMed Zheng P, Kissler S (2013) PTPN22 silencing in the NOD model indicates the type 1 diabetes-associated allele is not a loss-of-function variant. Diabetes 62:896–904CrossRefPubMedCentralPubMed
25.
Zurück zum Zitat Yeh LT, Miaw SC, Lin MH et al (2013) Different modulation of Ptpn22 in effector and regulatory T cells leads to attenuation of autoimmune diabetes in transgenic nonobese diabetic mice. J Immunol 191:594–607CrossRefPubMed Yeh LT, Miaw SC, Lin MH et al (2013) Different modulation of Ptpn22 in effector and regulatory T cells leads to attenuation of autoimmune diabetes in transgenic nonobese diabetic mice. J Immunol 191:594–607CrossRefPubMed
26.
Zurück zum Zitat Li XC, Turka LA (2010) An update on regulatory T cells in transplant tolerance and rejection. Nat Rev Nephrol 6:577–583CrossRefPubMed Li XC, Turka LA (2010) An update on regulatory T cells in transplant tolerance and rejection. Nat Rev Nephrol 6:577–583CrossRefPubMed
27.
Zurück zum Zitat Curotto de Lafaille M, Lafaille J (2009) Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 30:626–635CrossRefPubMed Curotto de Lafaille M, Lafaille J (2009) Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 30:626–635CrossRefPubMed
28.
Zurück zum Zitat Gagliani N, Magnani CF, Huber S et al (2013) Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med 19:739–746CrossRefPubMed Gagliani N, Magnani CF, Huber S et al (2013) Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med 19:739–746CrossRefPubMed
29.
Zurück zum Zitat Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK (2006) Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212:28–50CrossRefPubMed Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK (2006) Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212:28–50CrossRefPubMed
30.
Zurück zum Zitat Gagliani N, Gregori S, Jofra T et al (2011) Rapamycin combined with anti-CD45RB mAb and IL-10 or with G-CSF induces tolerance in a stringent mouse model of islet transplantation. PLoS One 6:e28434CrossRefPubMedCentralPubMed Gagliani N, Gregori S, Jofra T et al (2011) Rapamycin combined with anti-CD45RB mAb and IL-10 or with G-CSF induces tolerance in a stringent mouse model of islet transplantation. PLoS One 6:e28434CrossRefPubMedCentralPubMed
31.
Zurück zum Zitat Gagliani N, Jofra T, Valle A et al (2013) Transplant tolerance to pancreatic islets is initiated in the graft and sustained in the spleen. Am J Transplant 13:1963–1975CrossRefPubMed Gagliani N, Jofra T, Valle A et al (2013) Transplant tolerance to pancreatic islets is initiated in the graft and sustained in the spleen. Am J Transplant 13:1963–1975CrossRefPubMed
32.
Zurück zum Zitat Fousteri G, Dave A, Bot A, Juntti T, Omid S, von Herrath M (2010) Subcutaneous insulin B:9−23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNgamma. Diabetologia 53:1958–1970CrossRefPubMedCentralPubMed Fousteri G, Dave A, Bot A, Juntti T, Omid S, von Herrath M (2010) Subcutaneous insulin B:9−23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNgamma. Diabetologia 53:1958–1970CrossRefPubMedCentralPubMed
33.
Zurück zum Zitat Casares N, Rudilla F, Arribillaga L et al (2010) A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice. J Immunol 185:5150–5159CrossRefPubMed Casares N, Rudilla F, Arribillaga L et al (2010) A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice. J Immunol 185:5150–5159CrossRefPubMed
34.
Zurück zum Zitat Huang CT, Workman CJ, Flies D et al (2004) Role of LAG-3 in regulatory T cells. Immunity 21:503–513CrossRefPubMed Huang CT, Workman CJ, Flies D et al (2004) Role of LAG-3 in regulatory T cells. Immunity 21:503–513CrossRefPubMed
35.
Zurück zum Zitat Couper KN, Blount DG, de Souza JB, Suffia I, Belkaid Y, Riley EM (2007) Incomplete depletion and rapid regeneration of Foxp3+ regulatory T cells following anti-CD25 treatment in malaria-infected mice. J Immunol 178:4136–4146CrossRefPubMedCentralPubMed Couper KN, Blount DG, de Souza JB, Suffia I, Belkaid Y, Riley EM (2007) Incomplete depletion and rapid regeneration of Foxp3+ regulatory T cells following anti-CD25 treatment in malaria-infected mice. J Immunol 178:4136–4146CrossRefPubMedCentralPubMed
37.
Zurück zum Zitat Gordon JR, Ma Y, Churchman L, Gordon SA, Dawicki W (2014) Regulatory dendritic cells for immunotherapy in immunologic diseases. Front Immunol 5:7CrossRefPubMedCentralPubMed Gordon JR, Ma Y, Churchman L, Gordon SA, Dawicki W (2014) Regulatory dendritic cells for immunotherapy in immunologic diseases. Front Immunol 5:7CrossRefPubMedCentralPubMed
38.
39.
Zurück zum Zitat Fousteri G, Jofra T, Debernardis I et al (2014) The protein tyrosine phosphatase PTPN22 controls forkhead box protein 3 T regulatory cell induction but is dispensable for T helper type 1 cell polarization. Clin Exp Immunol 178:178–189CrossRefPubMed Fousteri G, Jofra T, Debernardis I et al (2014) The protein tyrosine phosphatase PTPN22 controls forkhead box protein 3 T regulatory cell induction but is dispensable for T helper type 1 cell polarization. Clin Exp Immunol 178:178–189CrossRefPubMed
40.
Zurück zum Zitat Gregori S, Goudy KS, Roncarolo MG (2012) The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. Front Immunol 3:30CrossRefPubMedCentralPubMed Gregori S, Goudy KS, Roncarolo MG (2012) The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. Front Immunol 3:30CrossRefPubMedCentralPubMed
Metadaten
Titel
Lack of the protein tyrosine phosphatase PTPN22 strengthens transplant tolerance to pancreatic islets in mice
verfasst von
Georgia Fousteri
Tatiana Jofra
Roberta Di Fonte
Nicola Gagliani
Cristina Morsiani
Angela Stabilini
Manuela Battaglia
Publikationsdatum
01.06.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 6/2015
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-015-3540-9

Weitere Artikel der Ausgabe 6/2015

Diabetologia 6/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.